ARTICLE | Clinical News

ND0612H: Phase IIa data

January 5, 2015 8:00 AM UTC

Top-line data from an Israeli Phase IIa trial in 16 advanced PD patients with motor fluctuations who were chronically treated with oral levodopa/carbidopa, the standard of care, showed that 2 versions of ND0612H formulated with different doses of carbidopa led to maximum daytime plasma levodopa concentrations of 1,333 and 1,436 ng/mL. ND0612H given with adjunct dosing of oral entacapone led to a maximum daytime plasma concentration of 1,807 ng/mL. ...